Atara Biotherapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst John Newman from Canaccord Genuity maintained a Buy rating on the stock and has a $17.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
John Newman’s rating is based on the potential approval of Atara Biotherapeutics’ tab-cel therapy, which could significantly impact the company’s future. The anticipated FDA approval for tab-cel, set for January 10th, 2026, is crucial, as it targets the ultra-rare EBV+ PTLD condition. Atara has addressed previous manufacturing concerns, and while there is a moderate risk of additional data requests from the FDA, the outlook remains positive.
Approval of tab-cel would not only trigger a $40 million milestone but also provide essential cash flow to revitalize Atara’s allogeneic CAR T program for autoimmune diseases. The company’s unique approach in this area could offer significant advantages, such as allowing patients to continue their current treatments without lymphodepletion. Furthermore, Atara’s current cash reserves are expected to sustain operations until the FDA decision, supporting the Buy rating with a price target of $17.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is neutral on the stock.